Terms: = Bone cancer AND PR, PGR, progesterone receptor AND Treatment
992 results:
1. High incidence of imperforate vagina in ADGRA3-deficient mice.
Kvam JM; Nybo ML; Torz L; Sustarsic RK; Jensen KHR; Nielsen JE; Frederiksen H; Gadgaard S; Spiess K; Poulsen SS; Thomsen JS; Cowin P; Blomberg Jensen M; Kurita T; Rosenkilde MM
BMC Biol; 2024 Apr; 22(1):77. PubMed ID: 38589878
[TBL] [Abstract] [Full Text] [Related]
2. [A Case of Recurrent Gastric cancer with Long-Term Control via Two Resections and Multidisciplinary treatment Including Nivolumab].
Bungo M; Takeno A; Hirao M; Hamakawa T; Yamamoto M; Matsui Y; Tokuyama S; Toshiyama R; Kawai K; Takahashi Y; Sakai K; Doi T; Goto K; Kato T; Takami K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1715-1717. PubMed ID: 38303183
[TBL] [Abstract] [Full Text] [Related]
3. Nomogram predicts survival and surgical benefits for patients with breast cancer with initial bone metastasis: A population-based study.
Zhou X; Liu M; Zheng Z; Cao X; Lin Y; Xu Y; Li Y; Wang HC; Sun Q
Cancer; 2024 Apr; 130(S8):1464-1475. PubMed ID: 38198445
[TBL] [Abstract] [Full Text] [Related]
4. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
5. Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
Furubayashi N; Minato A; Tomoda T; Hori Y; Kiyoshima K; Negishi T; Haraguchi Y; Koga T; Kuroiwa K; Fujimoto N; Nakamura M
Anticancer Res; 2023 Dec; 43(12):5689-5698. PubMed ID: 38030199
[TBL] [Abstract] [Full Text] [Related]
6. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
[TBL] [Abstract] [Full Text] [Related]
7. Deregulated MicroRNAs involved in P53 Signaling Pathway in Breast cancer with Focus on Triple-negative Breast cancer.
Naeimzadeh Y; Heidari Z; Razban V; Khajeh S
Curr Mol Pharmacol; 2024; 17(1):e18761429263841. PubMed ID: 37916633
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review.
Huang F; Ruan Y; He X; Lian H; Yang J
World J Surg Oncol; 2023 Oct; 21(1):342. PubMed ID: 37884941
[TBL] [Abstract] [Full Text] [Related]
9. Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.
Zhong X; Lin Y; Zhang W; Bi Q
Sci Rep; 2023 Oct; 13(1):18301. PubMed ID: 37880320
[TBL] [Abstract] [Full Text] [Related]
10. A multicenter retrospective analysis of clinical outcomes of intracranial chondrosarcoma in 26 patients.
Liu H; Li Z; Xue Y; Zhao T; Wu Y
Sci Rep; 2023 Sep; 13(1):14647. PubMed ID: 37669996
[TBL] [Abstract] [Full Text] [Related]
11. Lung cancer with breast metastasis: a case report and review of the literature.
Cao X; Chen P; Agyekum EA; Zhang Q; Qian X; Wu T; Chambers KH; Yin L
J Int Med Res; 2023 Jul; 51(7):3000605231188287. PubMed ID: 37523488
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic efficacy and safety results of 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer patients: first experience of a developing South Asian Country.
Parveen A; Fatima A; Fatima I; Khan IU; Shahid A
Nucl Med Commun; 2023 Oct; 44(10):876-887. PubMed ID: 37440195
[TBL] [Abstract] [Full Text] [Related]
13. Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
Soboń A; Drozd-Sokołowska J; Paszkiewicz-Kozik E; Popławska L; Morawska M; Tryc-Szponder J; Bołkun Ł; Rybka J; Pruszczyk K; Juda A; Majeranowski A; Iskierka-Jażdżewska E; Steckiewicz P; Wdowiak K; Budziszewska B; Jamroziak K; Hus I; Lech-Marańda E; Puła B
Ann Hematol; 2023 Aug; 102(8):2119-2126. PubMed ID: 37392368
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical Analysis of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm].
Cheng P; Wang QX; Wang LL; Guan J; Zhou Y; Zhang T; Su F; Chen LQ; Cao Y; Cheng H; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):896-901. PubMed ID: 37356957
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
Harada KI; Sato R; Bando Y; Sano A; Matsushita Y; Tamura K; Terakawa T; Furukawa J; Fujimoto N; Fujisawa M; Miyake H
Int J Urol; 2023 Sep; 30(9):772-777. PubMed ID: 37345413
[TBL] [Abstract] [Full Text] [Related]
16. Erdafitinib in the treatment of Metastatic Urothelial Carcinoma.
Castro-Alonso FJ; Beas-Lozano E; Remolina-Bonilla YA; Flaig TW; Bourlon MT
Oncology (Williston Park); 2023 Jun; 37(6):256-261. PubMed ID: 37343207
[TBL] [Abstract] [Full Text] [Related]
17. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A; Kutzera J; Geenen JJ; Pluim D; Hofland I; Sanders J; Lopez-Yurda M; Beijnen JH; Huitema ADR; Witteveen PO; Steeghs N; van Haaften G; van Vugt MATM; de Ridder J; Opdam FL
Gynecol Oncol; 2023 Jul; 174():239-246. PubMed ID: 37236033
[TBL] [Abstract] [Full Text] [Related]
18. Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Gao XN; Su YF; Li MY; Jing Y; Wang J; Xu L; Zhang LL; Wang A; Wang YZ; Zheng X; Li YF; Liu DH
Cancer Immunol Immunother; 2023 Aug; 72(8):2769-2782. PubMed ID: 37166484
[TBL] [Abstract] [Full Text] [Related]
19. Focal versus craniospinal radiation for disseminated atypical teratoid/rhabdoid tumor following favorable response to systemic therapy.
Aridgides PD; Mahajan A; Eaton B; Wang D; Timmerman B; Früwald MC; Nemes K; Deck J; Yamasaki K; Von Hoff K; Lafay-Cousin L; Reddy A; Lo AC
Pediatr Blood Cancer; 2023 Jul; 70(7):e30351. PubMed ID: 37073482
[TBL] [Abstract] [Full Text] [Related]
20. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
Yang J; Zhao B; Ling X; Li D; Zhao J; Lv Y; Wang G; Liu X; Li N; Yang J
BMC Cancer; 2023 Jan; 23(1):103. PubMed ID: 36717797
[TBL] [Abstract] [Full Text] [Related]
[Next]
